Xander Guarna
My name is Xander Guarna from the Jefferies Healthcare Investment Banking team, and it’s my pleasure to introduce Faraz Ali from Tenaya Therapeutics.
Faraz Ali
CEO, Interim Principal Financial Officer & Director
Thanks, and thanks to the Jefferies team for inviting us and giving us this opportunity to tell you a little bit more about Tenaya Therapeutics. We’re a publicly traded company. These are forward-looking statements. Our purpose is to transform and extend the lives of patients through the discovery, development and delivery of potentially curative therapies that target the underlying causes of heart disease.
There are a couple of things that make Tenaya unique. One, the unique focus on heart disease; two, we go after both rare and prevalent forms of heart disease; and three, that we actually are modality agnostic. And so we pursue gene therapy, small molecules, cardiac regeneration, gene editing, we truly follow the science, and those are some of the things that set us apart. We have 3 exciting clinical stage programs. And in the time I’ve been allocated today, I won’t be able to do justice to all of them. But most importantly, we have near-term catalysts in the form of readouts from our 2 gene therapy programs and including the potential for regulatory alignment on pivotal studies. So an exciting time for the company.
And in fact, that is the immediate opportunity for the company right now. The 2 gene therapy programs are TN-201 and TN-401, and those are moving relentlessly towards pivotal studies. Both are attractive because they address large opportunities. You can see 120,000 patients and 75,000 patients in
